Abstract Details
|
Kelly A. Boylan, MD
PRESENTER |
Dr. Boylan has nothing to disclose. |
| Jennifer Jolivert | No disclosure on file |
| Grace Wu | No disclosure on file |
| Eleanor Anderson (HUP Psychiatry) | No disclosure on file |
| Kathryn A. Davis, MD (University of Pennsylvania) | Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GW Pharmaceuticals/Jazz Pharmaceuticals. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spark Therapeutics. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UNEEG. Dr. Davis has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia Open. Dr. Davis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Pfizer. The institution of Dr. Davis has received research support from Eisai. The institution of Dr. Davis has received research support from Liminal. Dr. Davis has received publishing royalties from a publication relating to health care. |
| Michael Gelfand, MD, PhD (University of Pennsylvania) | Dr. Gelfand has received personal compensation in the range of $0-$499 for serving as a Consultant for Aquestive. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Livanova. The institution of Dr. Gelfand has received research support from Aquestive. The institution of Dr. Gelfand has received research support from Xenon. The institution of Dr. Gelfand has received research support from Cerevel. The institution of Dr. Gelfand has received research support from UNEEG. The institution of Dr. Gelfand has received research support from Livanova. The institution of Dr. Gelfand has received research support from UCB. The institution of Dr. Gelfand has received research support from SK Pharma. The institution of Dr. Gelfand has received research support from Otsuka. |
| Erin C. Conrad, MD (University of Pennsylvania) | Dr. Conrad has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epiminder. Dr. Conrad has stock in Humana. Dr. Conrad has stock in Lilly Eli. Dr. Conrad has stock in Medtronic. Dr. Conrad has stock in Merck. Dr. Conrad has stock in Nevro. Dr. Conrad has stock in Sanofi. Dr. Conrad has stock in United Health Group. |